Synthesis and biological evaluation of 2-oxo-pyrazine-3-carboxamide-yl nucleoside analogues and their epimers as inhibitors of influenza a viruses

Chemical Biology and Drug Design

Volumn 85, Issue 3, 2015, Pages 245-252

  Gao, Jingjing ^a   Luo, Xianjin ^a   Li, Yuhuan ^b   Gao, Rongmei ^b   Chen, Haifeng ^a   Ji, Dingjue ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Binding mode; Influenza a H1N1; Influenza a H3N2; Nucleoside analogues; Pyrazinecarboxamide derivatives

Indexed keywords

ANTIVIRUS AGENT; NUCLEOSIDE ANALOG; RNA DIRECTED RNA POLYMERASE; 4-(7-HYDROXY-1-(HYDROXYMETHYL)-2,5-DIOXABICYCLO(2.2.1)HEPTAN-3-YL)-3-OXO-3,4-DIHYDROPYRAZINE-2-CARBOXAMIDE; ENZYME INHIBITOR; NUCLEOSIDE; PYRAZINE DERIVATIVE;

ANTIVIRAL ACTIVITY; AQUEOUS SOLUTION; ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; ENVIRONMENTAL TEMPERATURE; EPIMER; INFLUENZA A (H1N1); INFLUENZA VIRUS A; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; SIMULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CELL SURVIVAL; CHEMISTRY; DOG; DRUG EFFECTS; ENZYME ACTIVE SITE; ENZYMOLOGY; HUMAN; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); MDCK CELL LINE; METABOLISM; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; VIRUS REPLICATION;

INFLUENZA A VIRUS;

ANIMALS; ANTIVIRAL AGENTS; BINDING SITES; CATALYTIC DOMAIN; CELL SURVIVAL; DOGS; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; MADIN DARBY CANINE KIDNEY CELLS; MOLECULAR DOCKING SIMULATION; NUCLEOSIDES; PYRAZINES; RNA REPLICASE; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 84923007215     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12382     Document Type: Article

References (24)

1. Weinstock D.M., Zuccotti G. (2009) The evolution of influenza resistance and treatment. JAMA;301:1066-1069.
2. Davies W.L., Grunert R.R., Haff R.F., McGahen J.W., Neumayer E.M., Paulshock M., Hoffmann C.E. et al. (1964) Antiviral activity of 1-adamantanamine (amantadine). Science;144:862-863.
3. Von Itzstein M., Wu W.Y., Kok G.B., Pegg M.S., Dyason J.C., Jin B., Penn C.R. et al. (1993) Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature;363:418-423.
4. Kim C.U., Lew W., Williams M.A., Liu H., Zhang L., Swaminathan S., Stevens R.C. et al. (1997) Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc;119:681-690.
5. De Clercq E. (2006) Antiviral agents active against influenza A viruses. Nat Rev Drug Discov;5:1015-1025.
6. Moscona A. (2005) Oseltamivir resistance - disabling our influenza defenses. N Engl J Med;353:2633-2636.
7. Furuta Y., Egawa H., Takahashi K., Takahashi Y., Uehara S., Murakami M. (2004) U.S. Patent No. 20,040,235,761. Washington, DC: U.S. Patent and Trademark Office.
8. Furuta Y., Takahashi K., Fukuda Y., Kuno M., Kamiyama T., Kozaki K., Shiraki K. (2002) In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother;46:977-981.
9. Sidwell R.W., Barnard D.L., Day C.W., Smee D.F., Bailey K.W., Wong M.H., Morrey J.D., Furuta Y. (2007) Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother;51:845-851.
10. Furuta Y., Takahashi K., Maekawa M., Maegawa H., Egawa H., Terashima N. (2004) T-1106, a novel pyrazine nucleoside, hepatitis C virus polymerase inhibitor [C]. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother. Washington, DC: American Society for Microbiology; p. 199-200.
11. Furuta Y., Takahashi K., Shiraki K., Sakamoto K., Smee D.F., Barnard D.L., Gowen B.B., Julander J.G., Morrey J.D. (2009) T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res;82:95-102.
12. Julander J.G., Shafer K., Smee D.F., Morrey J.D., Furuta Y. (2009) Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother;53:202-209.
13. Julander J.G., Furuta Y., Shafer K., Sidwell R.W. (2007) Activity of T-1106 in a hamster model of yellow fever virus infection. Antimicrob Agents Chemother; 51:1962-1966.
14. Gowen B.B., Wong M.H., Jung K.H., Smee D.F., Morrey J.D., Furuta Y. (2010) Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. Antiviral Res;86:121-127.
15. Wengel J. (1999) Synthesis of 3′-C-and 4′-C-branched oligodeoxynucleotides and the development of locked nucleic acid (LNA)[J]. Acc Chem Res;32:301-310.
16. Kaur H., Babu B.R., Maiti S. (2007) Perspectives on chemistry and therapeutic applications of locked nucleic acid (LNA). Chem Rev;107:4672-4697.
17. Torigoe H., Maruyama A., Obika S., Imanishi T., Katayama T. (2009) Synergistic stabilization of nucleic acid assembly by 2′-O, 4′-C-methylene-bridged nucleic acid modification and additions of comb-type cationic copolymers†. Biochemistry;48:3545-3553.
18. Rajwanshi V.K., Kumar R., Kofod-Hansen M., Wengel J. (1999) Synthesis and restricted furanose conformations of three novel bicyclic thymine nucleosides: a xylo-lna nucleoside, a 3′-o, 5′-c-methylene-linked nucleoside, and A 2′-O, 5′-C-methylene-linked nucleoside. J Chem Soc Perkin 1;11:1407-1414.
19. Sørensen M.D., Kværnø L., Bryld T., Håkansson A.E., Verbe ure B., Gaubert G., Herdewijn P., Wengel J. (2002) α-L-ribo-configured locked nucleic acid (α-L-LNA): synthesis and properties. J Am Chem Soc;124:2164-2176.
20. Reed L.J., Muench H. (1938) A simple method of estimating fifty percent endpoints. Am J Epidemiol; 27:493-497.
21. Koshkin A.A., Fensholdt J., Pfundheller H.M., Lomholt C. (2001) A simplified and efficient route to 2′-O, 4′-C-methylene-linked bicyclic ribonucleosides (locked nucleic acid). J Org Chem;66:8504-8512.
22. Rosenbohm C., Christensen S.M., Sørensen M.D., Pedersen D.S., Larsen L.E., Wengel J., Koch T. (2003) Synthesis of 2′-amino-LNA: a new strategy. Org Biomol Chem;1:655-663.
23. Sleeman K., Mishin V.P., Deyde V.M., Furuta Y., Klimov A.I., Gubareva L.V. (2010) In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A (H1N1) viruses. Antimicrob Agents Chemother; 54:2517-2524.
24. Sanner Michel F. (1999) Python: a programming language for software integration and development[J]. J Mol Graph Model;17:57-61.